SCHEMBL1748738

SCHEMBL1748738

COc1cc2c(-c3cc4c(C#N)ccnc4[nH]3)cn(CCN3CCN(C)CC3)c2cc1OC

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
IGF1R P08069 1/20 0.44
TBK1 Q9UHD2 4/20 0.43
SRC P12931 11/20 0.42
CDK9 P50750 2/20 0.40
CDC7 O00311 1/20 0.40
PIM1 P11309 1/20 0.40
FYN P06241 2/20 0.40
WEE2 P0C1S8 2/20 0.39
WEE1 P30291 2/20 0.39
PKMYT1 Q99640 2/20 0.39
CAMKK2 Q96RR4 3/20 0.39
ABL1 P00519 2/20 0.39
EGFR P00533 2/20 0.39
SYK P43405 2/20 0.39
STK25 O00506 1/20 0.39
CIT O14578 1/20 0.39
RIOK3 O14730 1/20 0.39
MAP2K7 O14733 1/20 0.39
CHEK1 O14757 1/20 0.39
CASK O14936 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1748870 0.87 IGF1R (0.46) IGF1RSRCCDK9CDC7PIM1
SCHEMBL1748948 0.82 IGF1R (0.64) IGF1RTBK1SRCCDK9CDC7
SCHEMBL1749006 0.82 IGF1R (0.67) IGF1RSRCSYKJAK2LCK
SCHEMBL1748413 0.79 IGF1R (0.63) IGF1RSYKDRD2DRD3FLT3
SCHEMBL1748609 0.79 CDK9 (0.47) IGF1RTBK1CDK9CAMKK2EGFR
Pyridine SCHEMBL5822323 0.78 IGF1R (0.60) IGF1RTBK1SRCCDK9CDC7
SCHEMBL2985824 0.77 IGF1R (0.38) IGF1RTBK1CDK9CDC7PIM1
SCHEMBL1748716 0.76 IGF1R (0.46) IGF1RTBK1SRCCDK9PIM1
SCHEMBL1749647 0.76 IGF1R (0.57) IGF1RTBK1CDK9PIM1FYN
SCHEMBL1748897 0.76 IGF1R (0.65) IGF1RCDK9SYKJAK2LCK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7528147-B2 Pyrrolo (2,3-b)pyridine derivatives, the preparation and the pharmaceutical use thereof in the form of kinase inhibitors AVENTIS PHARMA S.A. (FR) 2009-05-05 US claimed
US-20070093480-A1 Novel pyrrolo (2,3-b)pyridine derivatives, the preparation and the pharmaceutical use thereof in the form of kinase inhibitors AVENTIS PHARMA S.A. (FR) 2007-04-26 US claimed
US-7968566-B2 Pyrrolo(2,3-b) pyridine derivatives, the preparation and the pharmaceutical use thereof in the form of kinase inhibitors AVENTIS PHARMA S.A. (FR) 2011-06-28 US disclosed
US-20090233956-A1 NOVEL PYRROLO(2,3-b) PYRIDINE DERIVATIVES, THE PREPARATION AND THE PHARMACEUTICAL USE THEREOF IN THE FORM OF KINASE INHIBITORS AVENTIS PHARMA S.A. (FR) 2009-09-17 US disclosed
US-7528147-B2 Pyrrolo (2,3-b)pyridine derivatives, the preparation and the pharmaceutical use thereof in the form of kinase inhibitors AVENTIS PHARMA S.A. (FR) 2009-05-05 US disclosed
US-20070093480-A1 Novel pyrrolo (2,3-b)pyridine derivatives, the preparation and the pharmaceutical use thereof in the form of kinase inhibitors AVENTIS PHARMA S.A. (FR) 2007-04-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090233956-A1 NOVEL PYRROLO(2,3-b) PYRIDINE DERIVATIVES, THE PREPARATION AND THE PHARMACEUTICAL USE THEREOF IN THE FORM OF KINASE INHIBITORS MAP3K19, MAP4K2, MAP3K1 IGF1R 817/4885TBK1 322/4885SRC 187/4885
US-20070093480-A1 Novel pyrrolo (2,3-b)pyridine derivatives, the preparation and the pharmaceutical use thereof in the form of kinase inhibitors MAP3K19, MAP4K2, MAP3K1 IGF1R 817/4885TBK1 322/4885SRC 187/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.